Pharmaceutical Industry
Filter News
Found 13,014 articles
-
Voyager Therapeutics struck a deal with Illinois-based AbbVie to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease.
-
Court Documents Show Purdue’s Richard Sackler Did Not Want to Correct Misinformation About Streng...
2/22/2019
Court documents have shown how invested Richard Sackler was in the drive at Purdue Pharma to make OxyContin a success. A recent deposition that was unsealed has revealed just how far Sackler was willing to go. -
The Florida-based company points to inaccuracies in the letter Sanders sent earlier this month regarding the price of LEMS treatment Firdapse.
-
BioSpace Movers and Shakers: Feb. 22
2/22/2019
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more. -
Two-year follow-up data shows 100 percent overall survival and 100 percent event free survival in comparison to a historical standard of care from a historical control group.
-
Shares of Opiant Pharmaceuticals fell in trading Thursday and continue to slide in premarket trading this morning after the company announced its Phase II trial evaluating a naloxone nasal spray for the treatment of bulimia nervosa failed to meet primary endpoints and will discontinue the program.
-
3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets selected by Boehringer Ingelheim.
-
Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing
2/22/2019
Ocular Therapeutix™, Inc. announced that it has entered into a note purchase agreement with an accredited investor to issue $37.5 million aggregate principal amount of 6.00% subordinated convertible notes due 2026 pursuant to Regulation D promulgated under the Securities Act of 1933, as amended.
-
Aradigm Announces Receipt of Final FDA Minutes for the Type B Meeting on January 25, 2019
2/22/2019
At the Type B meeting, Aradigm presented the results of the Third Party Evaluation (TPE) completed in December 2019 that addressed the clinical issue raised by the FDA in the complete response letter (CRL) received in January 2018.
-
Oncopeptides AB: Year-end Report 2018
2/22/2019
At the company's Capital Markets Day in December, an updated strategy for Oncopeptides' business was presented
-
Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection) as Part of the National Mega Innovation Program in Beijing
2/22/2019
The Forum for the National Mega Innovation Program in conjunction with the press conference on the launch of Tyvyt®, hosted by Innovent Biologics, Inc., and co-sponsored by the China Association of Productivity Promotion Centers, was successfully held in Beijing
-
Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
-
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
-
Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz, a JAK inhibitor, has been a strong performer for the company, bringing in $1.77 billion in revenue last year. But now the company has indicated it intends to make a change in its post-marketing study due to safety concerns.
-
Since Amgen shut down its Bothell, Wash. site in 2014, life science employment growth has increased 13 percent across the state. According to The Seattle Times, companies across the region are in a scaling up process.
-
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
-
Lots of interesting biotech news from Asia, Europe and elsewhere was reported this week. From tapeworms to using a breathalyzer test in lung cancer diagnostics, the global biotech industry is exploding with ideas.
-
Johnson & Johnson’s iconic talcum powder product has been the subject of lawsuits and a scathing report that indicated the company allegedly knew that carcinogenic asbestos was sometimes found in the product. As a result, the company has received subpoenas from the federal government.
-
Seven pharma executives will enter the Congressional crucible next week as they face questions and concerns over the rising costs of prescription drugs.
-
Invitation to Sobi Capital Markets Day 14 May 2019
2/21/2019
Save the date for Swedish Orphan Biovitrum AB Capital Markets Day on 14 May 2019.